PURETHAL Mites 50,000 AUeq/ml clinical trials

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

This study is testing a new injection treatment for house dust mite allergy. It aims to see if it reduces allergy symptoms and is safe for adults with moderate to severe allergic rhinitis, with or without asthma. The treatment is given over one year.